Verastem | VSTM - Equity Capital And Reserves


Verastem reported $81.78M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Alaunos Therapeutics USD 1.29M 865K Mar/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Curis USD 12.71M 7.24M Mar/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
Incyte USD 6.34B 721.58M Jun/2026
Laboratory Of America USD 8.61B 121.8M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
TG Therapeutics USD 583.13M 64.89M Mar/2026
Verastem USD 81.78M 24.58M Mar/2026